A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF

Inclusion Criteria:

• Diagnosed with symptomatic paroxysmal atrial fibrillation (PAF) with (a) at leasttwo symptomatic atrial fibrillation (AF) episodes within last six months fromenrollment and (b) at least one AF episode electrocardiographically documented byelectrocardiogram (ECG); transtelephonic monitoring (TTM), Holter monitor, telemetrystrip or implanted device within 12 months prior to enrollment

• Failed at least one antiarrhythmic drug (AAD) (Class I or Class III) as evidenced byrecurrent symptomatic AF, intolerable side effects to the AAD, or contraindicationto the AAD

• Willing and capable of providing consent

• Able and willing to comply with all pre-, post- and follow-up testing andrequirements

Exclusion Criteria:

• AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiaccause (for example, documented obstructive sleep apnea, acute alcohol toxicity,etcetera)

• Previously diagnosed with persistent AF (greater than [>] 7 days in duration)

• Previous left atrium (LA) ablation or surgery

• Participants known to require ablation outside the pulmonary vein (PV) region (forexample, atrioventricular reentrant tachycardia, atrioventricular nodal reentrytachycardia, ventricular tachycardia, and Wolff-Parkinson-White), exceptcavotricuspid isthmus (CTI) lines for the ablation of typical right atrial flutter

• Documented severe dilatation of the LA (left anterior descending artery [LAD] >50mm)antero-posterior diameter on imaging within 6 months prior to enrollment

• Documented LA thrombus by imaging within 48 hours of the procedure

• Documented severely compromised left ventricular ejection fraction (LVEF less than [<] 40 percent [%]) by imaging within 6 months prior to enrollment

• Uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV

• History of blood clotting, bleeding abnormalities or contraindication toanticoagulation (heparin) except subjects with prior left atrial appendage closure

• Documented thromboembolic event (including transient ischemic attack [TIA]) withinthe past 12 months

• Participants with unstable angina, percutaneous coronary intervention or acutemyocardial infarction within 2 months

• Coronary artery bypass grafting (CABG) surgery within the past 6 months (180 days)

• Valvular cardiac surgical/percutaneous procedure (that is, ventriculotomy,atriotomy, valve repair or replacement and presence of a prosthetic valve)

• Unstable angina within 6 months

• Anticipated cardiac transplantation, cardiac surgery, or other major surgery withinthe next 12 months

• Significant pulmonary disease (for example, restrictive pulmonary disease,constrictive or chronic obstructive pulmonary disease) or any other disease ormalfunction of the lungs or respiratory system that produces severe chronic symptoms

• Significant congenital anomaly (for example, atrial septal defects [ASDs]) includingrepaired defects or medical problem that in the opinion of the investigator wouldpreclude enrollment in this study

• Prior diagnosis of pulmonary vein stenosis

• Pre-existing hemi diaphragmatic paralysis

• Acute illness, active systemic infection, or sepsis

• Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch orother abnormality that precludes catheter introduction or manipulation

• Severe mitral regurgitation (Regurgitant volume greater than or equal to [>=] 60milli liter (mL)/beat, Regurgitant fraction >= 50%, and/or Effective regurgitantorifice area >= 0.40 cm^2)

• Presence of implanted pacemaker, Implantable Cardioverter-Defibrillator (ICD),recently implanted (within 6 months) left atrial appendage occlusion (LAAO) deviceor other implanted metal cardiac device within cardiac space that may interfere withthe energy field created during the ablation procedure

• Presence of a condition that precludes vascular access

• Current enrollment in an investigational study evaluating another device or drug

• Women who are pregnant (as evidenced by pregnancy test if pre-menopausal),lactating, or who are of child-bearing age and plan on becoming pregnant during thecourse of the clinical investigation

• Life expectancy less than 12 months

• Presenting contra-indications for the devices used in the study, as indicated in therespective Instructions for Use (IFU)